Role of Hepatitis B Virus Surface Antigen Quantification in e Antigen Negative Chronic Hepatitis B Infection

R.M.Mukherjee

Authors

R.M.Mukherjee

HBsAg, quantification, ELISA, viral load, HBeAg negative, CHB infection

Abstract

Background/Aim: Hepatitis B surface antigen(HBsAg) is routinely detected qualitatively in Hepatitis B Virus(HBV) infection where its persistence beyond 6 months defines chronic hepatitis B(CHB) infection. Hepatitis B e antigen (HBeAg) usually indicates active HBV replication and risk of transmission of infection. In spite of the emerging use of chemiluminescence based quantitative HBsAg assays for therapeutic monitoring of the patients, we measured HBsAg concentration by sandwich ELISA as a cost effective alternative to ascertain the role of HBsAg levels as surrogate marker of untreated HBeAg negative subjects having CHB infection.

Downloads

How to Cite

Role of Hepatitis B Virus Surface Antigen Quantification in e Antigen Negative Chronic Hepatitis B Infection. (2014). Global Journal of Science Frontier Research, 13(G3), 1-5. https://www.journalofscience.org/index.php/GJSFR/article/view/1064

Download Citation

References

J Kao, D Chen (2002) Global control of hepatitis B virus infection. 2, 395-403.

M Brunetto, F Moriconi, F Bonino, G Lau, P Farci, C Yurdaydin, T Piratvisuth, K Luo, Y Wang, S Hadziyannis, E Wolf, P Mccloud, R Batrla, P Marcellin (2009) Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg , negative chronic hepatitis B. 49, 1141-1150.

Rami Moucari, Vincent Mackiewicz, Olivier Lada, Marie-Pierre Ripault, Corinne Castelnau, Michelle Martinot-Peignoux, Agnes Dauvergne, Tarik Asselah, Nathalie Boyer, Pierre Bedossa, Dominique Valla, Michel Vidaud, Marie-Hélène Nicolas-Chanoine, Patrick Marcellin (2009) Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients #. 49(4), 1151-1157.

H Chan, V Wong, A Tse, C Tse, A Chim, H Chan, G Wong (2007) Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. 5, 1462-1468.

R Ozaras, F Tabak, V Tahan, R Ozturk, H Akin, A Mert, H Senturk (2008) Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. 53, 2995-2998.

Giuseppe Realdi, Giovanna Fattovich, Stephanos Hadziyannis, Solko Schalm, Piero Almasio, Josè Sanchez-Tapias, Erik Christensen, Giuliano Giustina, Franco Noventa (1994) Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. 21(4), 656-666.

Chia‐ming Chu, Yun‐fan Liaw (2007) HBsAg seroclearance in asymptomatic carriers of high endemic areas. 45(5), 1187-1192.

Anna Lok, Brian Mcmahon (2009) Chronic hepatitis B: Update 2009 #. 50(3), 661-662.

R Biswas, E Tabor, C Hsia, D Wright, M Laycock, E Fiebig, L Peddada (2003) Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. 43, 788-798.

Wolfram Gerlich, Michael Kann (2005) Hepatitis B. 1226-1268.

Timothy Block, Anand Mehta, Baruch Blumberg, Raymond Dwek (2006) Does Rapid Oligomerization of Hepatitis B Envelope Proteins Play a Role in Resistance to Proteasome Degradation and Enhance Chronicity?. 25(3), 165-170.

W Gerlich, R Thomssen (1975) Standardidised detection of hepatitis B surface antigen; Determination of its serum concentration in weight units per volume. 30, 78-87.

H Joller-Jemelka, H Pfister, P Grob (1985) The prognostic significance of quantitative HBsAG determination in acute hepatitis B. 115, 1249-1256.

Barbara Burczynska, Kazimierz Madalinski, Joanna Pawlowska, Marek Woynarowski, Jerzy Socha, Wolfram Gerlich, Wulf Willems, Bogdan Wozniewicz, Józef Stachowski (1994) The value of quantitative measurement of HBeAg and HBsAg before interferon-α treatment of chronic hepatitis B in children. 21(6), 1097-1102.

W Gerlich, U Wend, D Glebe (2004) Quantitative assay of hepatitis B surface antigen in serum or plasma using laurel electrophoresis. 95, 57-63.

R Karakus, L Aral, B Basturk, C Aybay (2007) Development of a Highly Sensitive ELISA for Quantification of Hepatitis B Virus (HBV) Surface Antigen (HBsAg). 37, 87-92.

Johannes Wiegand, Heiner Wedemeyer, Andrea Finger, Benjamin Heidrich, Jens Rosenau, Gerd Michel, C Bock, Michael Manns, Hans Tillmann (2008) A Decline in Hepatitis B virus Surface Antigen (HBsAg) Predicts Clearance, but does not Correlate with Quantitative HBeAg or HBV DNA Levels. 13(4), 547-554.

M Brunetto, F Oliveri, P Colombatto, F Moriconi, P Ciccorossi, B Coco (2010) Use of HBsAg serum levels help to distinguish active from inactive HBV genotype D carriers. 139, 483-490.

Tin Nguyen, Alexander Thompson, Scott Bowden, Catherine Croagh, Sally Bell, Paul Desmond, Miriam Levy, Stephen Locarnini (2010) Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia. 52(4), 508-513.

Chien-Jen Chen, H Yang, J Su, C Jen, S You, S Lu (2006) Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level. 295(1), 65.

U Iloeje, H Yang, J Su, C Jen, S You, C Chen (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. 130, 678-686.

J Kim, J Choi, S Bae, S Yoon, J Yang, N Han (2010) Hepatitis B Virus Load in Serum Does Not Reflect Histologic Activity in Patients With Decompensated Cirrhosis. 8, 60-65.

R Mukherjee, P Balkumar Reddy, M Sasikala (2009) Identification of genotype B among Hepatitis B Virus-infected patients in Hyderabad, India. 8, 269-270.

Henry Chan, Alex Hui, Vincent Wong, Angel Chim, May‐ling Wong, Joseph Sung (2005) Long‐term follow‐up of peginterferon and lamivudine combination treatment in HBeAg‐positive chronic hepatitis B†. 41(6), 1357-1364.

Joseph Sung, May-Ling Wong, Scott Bowden, Choong-Tsek Liew, Alex Hui, Vincent Wong, Nancy Leung, Stephen Locarnini, Henry Chan (2005) Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy. 128(7), 1890-1897.

B Lapostolle, S Bowden, S Locarnini (2004) Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. 126, 1750-1758.

Uchenna Iloeje, Hwai-i. Yang, Chin-lan Jen, Jun Su, Li-yu Wang, San-lin You, Chien-jen Chen (2007) Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection. 5(8), 921-931.

R Mukherjee, P Balkumar Reddy, J Arava, P Rao, M Sasikala, R Gupta, D Reddy (2010) Relationship between serum HBsAg level, HBV DNA level, and peripheral immune cells in patients with chronic hepatitis B virus infection. 38(2± 13), 14-78.

3 Serum ALT(IU/ml). 57(41± 60), 10-372.

(null) Figure 2: (A) Standard curve of HBV DNA detected by FQ-PCR. (B) FQ-PCR amplification curves of standard, the concentrations of standards are 1 ×10 ⁸ copies/ml, 1 ×10 ⁷ copies/ml, 1 ×10 ⁶ copies/ml, 1 ×10 ⁵ copies/ml, 1 ×10 ⁴ copies/ml, respectively.. 4(45± 2), 54-58.

R Vranckx, J Cole, M Peetermans (1980) Correlation between concentration of HBsAg and the presence of HBeAg, anti-HBe and anti-HBc in chronic asymptomatic carriers of HBsAg. 8(6), 279-282.